

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Idhifa Prior Authorization Policy

- Idhifa® (enasidenib tablets – Celgene/Servier/Bristol-Myers Squibb)

REVIEW DATE: 02/23/2022; selected revision 06/22/2022

OVERVIEW

Idhifa, an isocitrate dehydrogenase-2 (*IDH2*) inhibitor, is indicated for the treatment of relapsed or refractory **acute myeloid leukemia** in adults with an *IDH2* mutation as detected by an FDA-approved test.¹

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines on acute myeloid leukemia (version 1.2022 – December 2, 2021) note Idhifa as an alternative for *IDH2* mutated AML in a variety of clinical scenarios. Idhifa is recommended for patients who have relapsed or refractory disease who have the *IDH2* mutation. Another clinical scenario is for treatment induction among patients ≥ 60 years of age who are not a candidate for intensive remission induction therapy or declines such therapy. In patients ≥ 60 years of age who had a response to previous lower intensity therapy, Idhifa can be continued. Both clinical scenarios apply to patients who are *IDH2* mutation positive.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Idhifa. All approvals are provided for the duration noted below.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Idhifa is recommended in those who meet the following criteria:

FDA-Approved Indication

1. **Acute Myeloid Leukemia.** Approve for 1 year if the patient meets the following criteria (A and B):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has isocitrate dehydrogenase-2 (*IDH2*)-mutation positive disease as detected by an approved test.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Idhifa is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Idhifa® tablets [prescribing information]. Summit, NJ: Celgene; November 2020.
2. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 1.2022 – December 2, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 16, 2022.

02/23/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

